Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 4 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2019 Filed Aug 12, 2019 13:57 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
SaleCommon Stock | 127 | $253.78 | $32,230.06 |
DisclosureSEC source: 0001543407-19-000043 · edgar.xml · nonDerivative · entry 1 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,930 Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 15:11 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
Exercise / conversionStock Appreciation Rights · Derivative | 2,865 | $0.00 Strike: $224.94 | $0.00 |
DisclosureSEC source: 0001543407-19-000042 · edgar.xml · derivative · entry 5 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,193 Underlying: Common Stock · 2,865 shares Expires 2028-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning June 1, 2019. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 15:11 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
SaleCommon Stock | 150 | $246.53 | $36,979.50 |
DisclosureSEC source: 0001543407-19-000042 · edgar.xml · nonDerivative · entry 4 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,057 Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 15:11 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
SaleCommon Stock | 250 | $246.56 | $61,640.00 |
DisclosureSEC source: 0001543407-19-000042 · edgar.xml · nonDerivative · entry 3 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,207 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $246.53 through $246.86. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 15:11 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
Disposition to issuerCommon Stock | 2,615 | $246.56 | $644,754.40 |
DisclosureSEC source: 0001543407-19-000042 · edgar.xml · nonDerivative · entry 2 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,457 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $246.53 through $246.86. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 15:11 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
Exercise / conversionCommon Stock | 2,865 | $224.94 | $644,453.10 |
DisclosureSEC source: 0001543407-19-000042 · edgar.xml · nonDerivative · entry 1 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 14:09 UTC |
Lim James CExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 2,773 | $0.00 Strike: $76.64 | $0.00 |
DisclosureSEC source: 0001543407-19-000040 · edgar.xml · derivative · entry 5 Lim James C · CIK 0001551804 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,855 Underlying: Common Stock · 2,773 shares Expires 2020-11-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 23, 2011. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 14:09 UTC |
Lim James CExecutive Vice President
|
SaleCommon Stock | 1,929 | $252.01 | $486,127.29 |
DisclosureSEC source: 0001543407-19-000040 · edgar.xml · nonDerivative · entry 3 Lim James C · CIK 0001551804 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,193 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $252.00 through $252.04. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 14:09 UTC |
Lim James CExecutive Vice President
|
Disposition to issuerCommon Stock | 844 | $252.01 | $212,696.44 |
DisclosureSEC source: 0001543407-19-000040 · edgar.xml · nonDerivative · entry 2 Lim James C · CIK 0001551804 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,122 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $252.00 through $252.04. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 14:09 UTC |
Lim James CExecutive Vice President
|
Exercise / conversionCommon Stock | 2,773 | $76.64 | $212,522.72 |
DisclosureSEC source: 0001543407-19-000040 · edgar.xml · nonDerivative · entry 1 Lim James C · CIK 0001551804 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 14:49 UTC |
Goette RolandEVP and President, EMEA
|
Exercise / conversionStock Appreciation Rights · Derivative | 2,463 | $0.00 Strike: $75.63 | $0.00 |
DisclosureSEC source: 0001543407-19-000041 · edgar.xml · derivative · entry 5 Goette Roland · CIK 0001708067 · EVP and President, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,463 shares Expires 2019-11-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 24, 2010. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 14:49 UTC |
Goette RolandEVP and President, EMEA
|
SaleCommon Stock | 1,717 | $249.88 | $429,043.96 |
DisclosureSEC source: 0001543407-19-000041 · edgar.xml · nonDerivative · entry 3 Goette Roland · CIK 0001708067 · EVP and President, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,247 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $249.83 through $249.88. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 14:49 UTC |
Goette RolandEVP and President, EMEA
|
Disposition to issuerCommon Stock | 746 | $249.88 | $186,410.48 |
DisclosureSEC source: 0001543407-19-000041 · edgar.xml · nonDerivative · entry 2 Goette Roland · CIK 0001708067 · EVP and President, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,964 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $249.83 through $249.88. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 14:49 UTC |
Goette RolandEVP and President, EMEA
|
Exercise / conversionCommon Stock | 2,463 | $75.63 | $186,276.69 |
DisclosureSEC source: 0001543407-19-000041 · edgar.xml · nonDerivative · entry 1 Goette Roland · CIK 0001708067 · EVP and President, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 12:49 UTC |
Jones Christopher Ian MontagueDirector
|
GrantRights to Common Stock Under 1996 Directors Deferral Plan · Derivative | 106 | $249.86 | $26,485.16 |
DisclosureSEC source: 0001543407-19-000039 · edgar.xml · derivative · entry 1 Jones Christopher Ian Montague · CIK 0001292762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,873 Underlying: Common Stock · 106 shares Expires not disclosed F1 · derivative.exercise_price: The securities convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F2 · derivative.expiration_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F3 · balance_after: Includes rights acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 12:46 UTC |
SCOTT BERTRAM LDirector
|
GrantRights to Common Stock Under 1996 Directors Deferral Plan · Derivative | 106 | $249.86 | $26,485.16 |
DisclosureSEC source: 0001543407-19-000038 · edgar.xml · derivative · entry 1 SCOTT BERTRAM L · CIK 0001221780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,164 Underlying: Common Stock · 106 shares Expires not disclosed F1 · derivative.exercise_price: The securities convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F2 · derivative.expiration_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F3 · balance_after: Includes rights acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| August 07, 2019 Filed Aug 7, 2019 18:56 UTC |
Fraser ClaireDirector
|
SaleCommon Stock | 1,429 | $243.26 | $347,618.54 |
DisclosureSEC source: 0001543407-19-000037 · edgar.xml · nonDerivative · entry 1 Fraser Claire · CIK 0001382031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,544 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| June 24, 2019 Filed Sep 10, 2019 14:50 UTC |
FORLENZA VINCENT ADirector · Chairman, CEO and President
|
GiftCommon Stock | 4,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-19-000050 · edgar.xml · nonDerivative · entry 2 FORLENZA VINCENT A · CIK 0001221787 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,645 Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 17:57 UTC |
Campion Simon DEVP and Segment President
|
SaleCommon Stock | 2,903 | $236.94 | $687,836.82 |
DisclosureSEC source: 0001543407-19-000036 · edgar.xml · nonDerivative · entry 1 Campion Simon D · CIK 0001751919 · EVP and Segment President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,408 Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 13:24 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
Exercise / conversionStock Appreciation Rights · Derivative | 2,865 | $0.00 Strike: $224.94 | $0.00 |
DisclosureSEC source: 0001543407-19-000035 · edgar.xml · derivative · entry 4 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,058 Underlying: Common Stock · 2,865 shares Expires 2028-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning June 1, 2019. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 13:24 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
SaleCommon Stock | 191 | $241.03 | $46,036.73 |
DisclosureSEC source: 0001543407-19-000035 · edgar.xml · nonDerivative · entry 3 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,207 Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 13:24 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
Disposition to issuerCommon Stock | 2,674 | $241.03 | $644,514.22 |
DisclosureSEC source: 0001543407-19-000035 · edgar.xml · nonDerivative · entry 2 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,398 Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 13:24 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
Exercise / conversionCommon Stock | 2,865 | $224.94 | $644,453.10 |
DisclosureSEC source: 0001543407-19-000035 · edgar.xml · nonDerivative · entry 1 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 17:25 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
SaleCommon Stock | 275 | $235.00 | $64,625.00 |
DisclosureSEC source: 0001543407-19-000034 · edgar.xml · nonDerivative · entry 2 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,207 Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 17:25 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
GrantCommon Stock | 12,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-19-000034 · edgar.xml · nonDerivative · entry 1 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,482 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. Read SEC document |
| June 01, 2019 Filed Jun 3, 2019 14:47 UTC |
Kaltenbach PatrickEVP & Pres Life Sciences
|
Tax withholdingCommon Stock | 292 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-19-000033 · edgar.xml · nonDerivative · entry 1 Kaltenbach Patrick · CIK 0001625775 · EVP & Pres Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,103 F1 · shares: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units as previously reported on Table I. Read SEC document |
| May 21, 2019 Filed May 23, 2019 16:30 UTC |
Khichi Samrat S.EVP and General Counsel
|
SaleCommon Stock | 16,085 | $234.68 | $3,774,827.80 |
DisclosureSEC source: 0001543407-19-000031 · edgar.xml · nonDerivative · entry 1 Khichi Samrat S. · CIK 0001612227 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,608 F1 · shares: Includes shares acquired through dividend reinvestment since the last report filed by the reporting person. F2 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $233.94 through $235.14. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| May 13, 2019 Filed May 14, 2019 18:02 UTC |
Larson Betty DEVP HR & CHRO
|
Exercise / conversionStock Appreciation Rights · Derivative | 2,200 | $0.00 Strike: $97.14 | $0.00 |
DisclosureSEC source: 0001543407-19-000030 · edgar.xml · derivative · entry 5 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893 Underlying: Common Stock · 2,200 shares Expires 2024-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning September 2, 2015. Read SEC document |
| May 13, 2019 Filed May 14, 2019 18:02 UTC |
Larson Betty DEVP HR & CHRO
|
SaleCommon Stock | 450 | $224.91 | $101,209.50 |
DisclosureSEC source: 0001543407-19-000030 · edgar.xml · nonDerivative · entry 4 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,843 Read SEC document |
| May 13, 2019 Filed May 14, 2019 18:02 UTC |
Larson Betty DEVP HR & CHRO
|
SaleCommon Stock | 1,250 | $224.99 | $281,237.50 |
DisclosureSEC source: 0001543407-19-000030 · edgar.xml · nonDerivative · entry 3 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,293 Read SEC document |
| May 13, 2019 Filed May 14, 2019 18:02 UTC |
Larson Betty DEVP HR & CHRO
|
Disposition to issuerCommon Stock | 950 | $224.99 | $213,740.50 |
DisclosureSEC source: 0001543407-19-000030 · edgar.xml · nonDerivative · entry 2 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,543 Read SEC document |
| May 13, 2019 Filed May 14, 2019 18:02 UTC |
Larson Betty DEVP HR & CHRO
|
Exercise / conversionCommon Stock | 2,200 | $97.14 | $213,708.00 |
DisclosureSEC source: 0001543407-19-000030 · edgar.xml · nonDerivative · entry 1 Larson Betty D · CIK 0001617903 · EVP HR & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2019 Filed May 13, 2019 17:02 UTC |
SCOTT BERTRAM LDirector
|
GrantRights to Common Stock Under 1996 Directors Deferral Plan · Derivative | 111 | $240.74 | $26,722.14 |
DisclosureSEC source: 0001543407-19-000029 · edgar.xml · derivative · entry 1 SCOTT BERTRAM L · CIK 0001221780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,058 Underlying: Common Stock · 111 shares Expires not disclosed F1 · derivative.exercise_price: The securities convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F2 · derivative.expiration_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F3 · balance_after: Includes rights acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| May 10, 2019 Filed May 13, 2019 17:01 UTC |
Jones Christopher Ian MontagueDirector
|
GrantRights to Common Stock Under 1996 Directors Deferral Plan · Derivative | 111 | $240.74 | $26,722.14 |
DisclosureSEC source: 0001543407-19-000028 · edgar.xml · derivative · entry 1 Jones Christopher Ian Montague · CIK 0001292762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,767 Underlying: Common Stock · 111 shares Expires not disclosed F1 · derivative.exercise_price: The securities convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F2 · derivative.expiration_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F3 · balance_after: Includes rights acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| April 17, 2019 Filed May 30, 2019 17:12 UTC |
BURZIK CATHERINE MDirector
|
SaleCommon Stock | 45 | $223.04 | $10,036.80 |
DisclosureSEC source: 0001543407-19-000032 · edgar.xml · nonDerivative · entry 4 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,007 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| April 16, 2019 Filed May 30, 2019 17:12 UTC |
BURZIK CATHERINE MDirector
|
PurchaseCommon Stock | 30 | $247.96 | $7,438.80 |
DisclosureSEC source: 0001543407-19-000032 · edgar.xml · nonDerivative · entry 3 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,052 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| April 16, 2019 Filed Sep 10, 2019 14:50 UTC |
FORLENZA VINCENT ADirector · Chairman, CEO and President
|
GiftCommon Stock | 7,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-19-000050 · edgar.xml · nonDerivative · entry 1 FORLENZA VINCENT A · CIK 0001221787 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,671 F1 · shares: These shares were previously reported as held in a grantor retained annuity trust and were distributed to the reporting person on April 16, 2019. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:27 UTC |
FORLENZA VINCENT ADirector · Chairman, CEO and President
|
Exercise / conversionStock Appreciation Rights · Derivative | 11,878 | $0.00 Strike: $76.64 | $0.00 |
DisclosureSEC source: 0001543407-19-000027 · edgar.xml · derivative · entry 6 FORLENZA VINCENT A · CIK 0001221787 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,686 Underlying: Common Stock · 11,878 shares Expires 2020-11-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 23, 2011. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:27 UTC |
FORLENZA VINCENT ADirector · Chairman, CEO and President
|
SaleCommon Stock | 8,309 | $255.13 | $2,119,875.17 |
DisclosureSEC source: 0001543407-19-000027 · edgar.xml · nonDerivative · entry 3 FORLENZA VINCENT A · CIK 0001221787 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,907 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $255 through $256.01. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:27 UTC |
FORLENZA VINCENT ADirector · Chairman, CEO and President
|
Disposition to issuerCommon Stock | 3,469 | $255.13 | $885,045.97 |
DisclosureSEC source: 0001543407-19-000027 · edgar.xml · nonDerivative · entry 2 FORLENZA VINCENT A · CIK 0001221787 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,216 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $255 through $256.01. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:27 UTC |
FORLENZA VINCENT ADirector · Chairman, CEO and President
|
Exercise / conversionCommon Stock | 11,878 | $76.64 | $910,329.92 |
DisclosureSEC source: 0001543407-19-000027 · edgar.xml · nonDerivative · entry 1 FORLENZA VINCENT A · CIK 0001221787 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:13 UTC |
Mas Ribo AlbertoEVP and Pres, Life Sciences
|
Exercise / conversionStock Appreciation Rights · Derivative | 3,483 | $0.00 Strike: $108.89 | $0.00 |
DisclosureSEC source: 0001543407-19-000026 · edgar.xml · derivative · entry 7 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,483 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 26, 2014. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:13 UTC |
Mas Ribo AlbertoEVP and Pres, Life Sciences
|
SaleCommon Stock | 109 | $255.00 | $27,795.00 |
DisclosureSEC source: 0001543407-19-000026 · edgar.xml · nonDerivative · entry 4 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,482 Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:13 UTC |
Mas Ribo AlbertoEVP and Pres, Life Sciences
|
SaleCommon Stock | 1,995 | $255.00 | $508,725.00 |
DisclosureSEC source: 0001543407-19-000026 · edgar.xml · nonDerivative · entry 3 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,591 Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:13 UTC |
Mas Ribo AlbertoEVP and Pres, Life Sciences
|
Disposition to issuerCommon Stock | 1,488 | $255.00 | $379,440.00 |
DisclosureSEC source: 0001543407-19-000026 · edgar.xml · nonDerivative · entry 2 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,586 Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 14:13 UTC |
Mas Ribo AlbertoEVP and Pres, Life Sciences
|
Exercise / conversionCommon Stock | 3,483 | $108.89 | $379,263.87 |
DisclosureSEC source: 0001543407-19-000026 · edgar.xml · nonDerivative · entry 1 Mas Ribo Alberto · CIK 0001686270 · EVP and Pres, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:05 UTC |
FORLENZA VINCENT ADirector · Chairman, CEO and President
|
Exercise / conversionStock Appreciation Rights · Derivative | 4,465 | $0.00 Strike: $76.64 | $0.00 |
DisclosureSEC source: 0001543407-19-000024 · edgar.xml · derivative · entry 6 FORLENZA VINCENT A · CIK 0001221787 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,564 Underlying: Common Stock · 4,465 shares Expires 2020-11-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock appreciation rights vest in four annual installments beginning November 23, 2011. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:05 UTC |
FORLENZA VINCENT ADirector · Chairman, CEO and President
|
SaleCommon Stock | 3,123 | $255.03 | $796,458.69 |
DisclosureSEC source: 0001543407-19-000024 · edgar.xml · nonDerivative · entry 3 FORLENZA VINCENT A · CIK 0001221787 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,907 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $255 through $255.14. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:05 UTC |
FORLENZA VINCENT ADirector · Chairman, CEO and President
|
Disposition to issuerCommon Stock | 1,342 | $255.03 | $342,250.26 |
DisclosureSEC source: 0001543407-19-000024 · edgar.xml · nonDerivative · entry 2 FORLENZA VINCENT A · CIK 0001221787 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,030 F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $255 through $255.14. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:05 UTC |
FORLENZA VINCENT ADirector · Chairman, CEO and President
|
Exercise / conversionCommon Stock | 4,465 | $76.64 | $342,197.60 |
DisclosureSEC source: 0001543407-19-000024 · edgar.xml · nonDerivative · entry 1 FORLENZA VINCENT A · CIK 0001221787 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.